nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP2D6—Hydroxyurea—psoriasis	0.0581	0.0849	CbGbCtD
Methazolamide—SLC22A6—Cyclosporine—psoriasis	0.0551	0.0805	CbGbCtD
Methazolamide—CYP2C19—Cholecalciferol—psoriasis	0.0463	0.0677	CbGbCtD
Methazolamide—CYP3A4—Calcitriol—psoriasis	0.0435	0.0635	CbGbCtD
Methazolamide—CYP2C9—Cholecalciferol—psoriasis	0.0385	0.0563	CbGbCtD
Methazolamide—CYP2D6—Cholecalciferol—psoriasis	0.0352	0.0514	CbGbCtD
Methazolamide—CYP3A4—Methoxsalen—psoriasis	0.0338	0.0494	CbGbCtD
Methazolamide—CYP2C19—Prednisone—psoriasis	0.0321	0.0469	CbGbCtD
Methazolamide—CYP2E1—Dexamethasone—psoriasis	0.032	0.0467	CbGbCtD
Methazolamide—CYP2C19—Cyclosporine—psoriasis	0.0304	0.0445	CbGbCtD
Methazolamide—SLC22A6—Methotrexate—psoriasis	0.0292	0.0426	CbGbCtD
Methazolamide—CYP2C9—Cyclosporine—psoriasis	0.0253	0.037	CbGbCtD
Methazolamide—CYP2D6—Cyclosporine—psoriasis	0.0231	0.0338	CbGbCtD
Methazolamide—CYP3A4—Cholecalciferol—psoriasis	0.0224	0.0327	CbGbCtD
Methazolamide—CYP2C19—Dexamethasone—psoriasis	0.02	0.0293	CbGbCtD
Methazolamide—CYP3A4—Mycophenolate mofetil—psoriasis	0.0194	0.0284	CbGbCtD
Methazolamide—CYP3A4—Triamcinolone—psoriasis	0.0194	0.0284	CbGbCtD
Methazolamide—CYP2C9—Dexamethasone—psoriasis	0.0167	0.0243	CbGbCtD
Methazolamide—CYP3A4—Betamethasone—psoriasis	0.0167	0.0243	CbGbCtD
Methazolamide—CYP3A4—Prednisolone—psoriasis	0.0164	0.024	CbGbCtD
Methazolamide—CYP3A4—Hydrocortisone—psoriasis	0.0156	0.0228	CbGbCtD
Methazolamide—CYP3A4—Prednisone—psoriasis	0.0155	0.0227	CbGbCtD
Methazolamide—CYP2D6—Dexamethasone—psoriasis	0.0152	0.0223	CbGbCtD
Methazolamide—CYP3A4—Cyclosporine—psoriasis	0.0147	0.0215	CbGbCtD
Methazolamide—CYP3A4—Dexamethasone—psoriasis	0.00969	0.0142	CbGbCtD
Methazolamide—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.000909	0.0648	CbGpPWpGaD
Methazolamide—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000701	0.05	CbGpPWpGaD
Methazolamide—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000645	0.046	CbGpPWpGaD
Methazolamide—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00064	0.0456	CbGpPWpGaD
Methazolamide—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000602	0.0429	CbGpPWpGaD
Methazolamide—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000594	0.00197	CcSEcCtD
Methazolamide—Photosensitivity—Methotrexate—psoriasis	0.000593	0.00197	CcSEcCtD
Methazolamide—Polyuria—Methotrexate—psoriasis	0.000593	0.00197	CcSEcCtD
Methazolamide—Tinnitus—Mycophenolate mofetil—psoriasis	0.000593	0.00197	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.00059	0.00196	CcSEcCtD
Methazolamide—Discomfort—Mycophenolic acid—psoriasis	0.00059	0.00196	CcSEcCtD
Methazolamide—Fatigue—Hydroxyurea—psoriasis	0.00059	0.00196	CcSEcCtD
Methazolamide—Nausea—Calcitriol—psoriasis	0.000582	0.00193	CcSEcCtD
Methazolamide—Hepatic failure—Methotrexate—psoriasis	0.00058	0.00192	CcSEcCtD
Methazolamide—Confusional state—Mycophenolic acid—psoriasis	0.000577	0.00192	CcSEcCtD
Methazolamide—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.000564	0.0402	CbGpPWpGaD
Methazolamide—Feeling abnormal—Hydroxyurea—psoriasis	0.000563	0.00187	CcSEcCtD
Methazolamide—Dysgeusia—Cyclosporine—psoriasis	0.000556	0.00185	CcSEcCtD
Methazolamide—Vomiting—Acitretin—psoriasis	0.000554	0.00184	CcSEcCtD
Methazolamide—Vomiting—Fluocinolone Acetonide—psoriasis	0.000552	0.00183	CcSEcCtD
Methazolamide—Rash—Acitretin—psoriasis	0.000549	0.00182	CcSEcCtD
Methazolamide—Dermatitis—Acitretin—psoriasis	0.000549	0.00182	CcSEcCtD
Methazolamide—Rash—Fluocinolone Acetonide—psoriasis	0.000548	0.00182	CcSEcCtD
Methazolamide—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000547	0.00182	CcSEcCtD
Methazolamide—Anorexia—Mycophenolic acid—psoriasis	0.000546	0.00181	CcSEcCtD
Methazolamide—Headache—Acitretin—psoriasis	0.000546	0.00181	CcSEcCtD
Methazolamide—Headache—Fluocinolone Acetonide—psoriasis	0.000544	0.00181	CcSEcCtD
Methazolamide—Dysgeusia—Mycophenolate mofetil—psoriasis	0.000542	0.0018	CcSEcCtD
Methazolamide—Body temperature increased—Hydroxyurea—psoriasis	0.000541	0.00179	CcSEcCtD
Methazolamide—Ill-defined disorder—Cyclosporine—psoriasis	0.000527	0.00175	CcSEcCtD
Methazolamide—Nausea—Acitretin—psoriasis	0.000517	0.00172	CcSEcCtD
Methazolamide—Nausea—Fluocinolone Acetonide—psoriasis	0.000516	0.00171	CcSEcCtD
Methazolamide—Paraesthesia—Mycophenolic acid—psoriasis	0.000514	0.00171	CcSEcCtD
Methazolamide—Ill-defined disorder—Mycophenolate mofetil—psoriasis	0.000514	0.00171	CcSEcCtD
Methazolamide—Malaise—Cyclosporine—psoriasis	0.000512	0.0017	CcSEcCtD
Methazolamide—Vertigo—Cyclosporine—psoriasis	0.00051	0.00169	CcSEcCtD
Methazolamide—Somnolence—Mycophenolic acid—psoriasis	0.000509	0.00169	CcSEcCtD
Methazolamide—Leukopenia—Cyclosporine—psoriasis	0.000508	0.00169	CcSEcCtD
Methazolamide—Dyspepsia—Mycophenolic acid—psoriasis	0.000504	0.00167	CcSEcCtD
Methazolamide—Malaise—Mycophenolate mofetil—psoriasis	0.000499	0.00166	CcSEcCtD
Methazolamide—Decreased appetite—Mycophenolic acid—psoriasis	0.000498	0.00165	CcSEcCtD
Methazolamide—Vertigo—Mycophenolate mofetil—psoriasis	0.000498	0.00165	CcSEcCtD
Methazolamide—Leukopenia—Mycophenolate mofetil—psoriasis	0.000496	0.00165	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000494	0.00164	CcSEcCtD
Methazolamide—Fatigue—Mycophenolic acid—psoriasis	0.000494	0.00164	CcSEcCtD
Methazolamide—Convulsion—Cyclosporine—psoriasis	0.000492	0.00163	CcSEcCtD
Methazolamide—Asthenia—Hydroxyurea—psoriasis	0.000491	0.00163	CcSEcCtD
Methazolamide—Convulsion—Mycophenolate mofetil—psoriasis	0.00048	0.00159	CcSEcCtD
Methazolamide—Ill-defined disorder—Prednisolone—psoriasis	0.000479	0.00159	CcSEcCtD
Methazolamide—Discomfort—Cyclosporine—psoriasis	0.000478	0.00158	CcSEcCtD
Methazolamide—Feeling abnormal—Mycophenolic acid—psoriasis	0.000472	0.00157	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Methotrexate—psoriasis	0.000469	0.00156	CcSEcCtD
Methazolamide—Ill-defined disorder—Hydrocortisone—psoriasis	0.000468	0.00155	CcSEcCtD
Methazolamide—Diarrhoea—Hydroxyurea—psoriasis	0.000468	0.00155	CcSEcCtD
Methazolamide—Confusional state—Cyclosporine—psoriasis	0.000467	0.00155	CcSEcCtD
Methazolamide—Malaise—Prednisolone—psoriasis	0.000466	0.00155	CcSEcCtD
Methazolamide—Discomfort—Mycophenolate mofetil—psoriasis	0.000466	0.00155	CcSEcCtD
Methazolamide—Dysgeusia—Triamcinolone—psoriasis	0.000465	0.00154	CcSEcCtD
Methazolamide—Vertigo—Prednisolone—psoriasis	0.000464	0.00154	CcSEcCtD
Methazolamide—Anaphylactic shock—Cyclosporine—psoriasis	0.000463	0.00154	CcSEcCtD
Methazolamide—Confusional state—Mycophenolate mofetil—psoriasis	0.000456	0.00151	CcSEcCtD
Methazolamide—Malaise—Hydrocortisone—psoriasis	0.000455	0.00151	CcSEcCtD
Methazolamide—Vertigo—Hydrocortisone—psoriasis	0.000453	0.0015	CcSEcCtD
Methazolamide—Body temperature increased—Mycophenolic acid—psoriasis	0.000453	0.0015	CcSEcCtD
Methazolamide—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000452	0.0015	CcSEcCtD
Methazolamide—Convulsion—Prednisolone—psoriasis	0.000448	0.00149	CcSEcCtD
Methazolamide—Anorexia—Cyclosporine—psoriasis	0.000442	0.00147	CcSEcCtD
Methazolamide—Ill-defined disorder—Triamcinolone—psoriasis	0.000441	0.00146	CcSEcCtD
Methazolamide—Convulsion—Hydrocortisone—psoriasis	0.000437	0.00145	CcSEcCtD
Methazolamide—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000435	0.031	CbGpPWpGaD
Methazolamide—Vomiting—Hydroxyurea—psoriasis	0.000435	0.00144	CcSEcCtD
Methazolamide—Discomfort—Prednisolone—psoriasis	0.000435	0.00144	CcSEcCtD
Methazolamide—Rash—Hydroxyurea—psoriasis	0.000431	0.00143	CcSEcCtD
Methazolamide—Anorexia—Mycophenolate mofetil—psoriasis	0.000431	0.00143	CcSEcCtD
Methazolamide—Dermatitis—Hydroxyurea—psoriasis	0.000431	0.00143	CcSEcCtD
Methazolamide—Malaise—Triamcinolone—psoriasis	0.000428	0.00142	CcSEcCtD
Methazolamide—Headache—Hydroxyurea—psoriasis	0.000428	0.00142	CcSEcCtD
Methazolamide—Pancytopenia—Methotrexate—psoriasis	0.000428	0.00142	CcSEcCtD
Methazolamide—Vertigo—Triamcinolone—psoriasis	0.000427	0.00142	CcSEcCtD
Methazolamide—Discomfort—Hydrocortisone—psoriasis	0.000424	0.00141	CcSEcCtD
Methazolamide—Anaphylactic shock—Prednisolone—psoriasis	0.000422	0.0014	CcSEcCtD
Methazolamide—Paraesthesia—Cyclosporine—psoriasis	0.000416	0.00138	CcSEcCtD
Methazolamide—Somnolence—Cyclosporine—psoriasis	0.000412	0.00137	CcSEcCtD
Methazolamide—Anaphylactic shock—Hydrocortisone—psoriasis	0.000412	0.00137	CcSEcCtD
Methazolamide—Convulsion—Triamcinolone—psoriasis	0.000412	0.00137	CcSEcCtD
Methazolamide—Photosensitivity reaction—Methotrexate—psoriasis	0.000411	0.00136	CcSEcCtD
Methazolamide—Asthenia—Mycophenolic acid—psoriasis	0.000411	0.00136	CcSEcCtD
Methazolamide—Dyspepsia—Cyclosporine—psoriasis	0.000408	0.00135	CcSEcCtD
Methazolamide—Nausea—Hydroxyurea—psoriasis	0.000406	0.00135	CcSEcCtD
Methazolamide—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000406	0.00135	CcSEcCtD
Methazolamide—Decreased appetite—Cyclosporine—psoriasis	0.000403	0.00134	CcSEcCtD
Methazolamide—Somnolence—Mycophenolate mofetil—psoriasis	0.000402	0.00133	CcSEcCtD
Methazolamide—Drowsiness—Methotrexate—psoriasis	0.000401	0.00133	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Cyclosporine—psoriasis	0.0004	0.00133	CcSEcCtD
Methazolamide—Ill-defined disorder—Betamethasone—psoriasis	0.0004	0.00133	CcSEcCtD
Methazolamide—Ill-defined disorder—Dexamethasone—psoriasis	0.0004	0.00133	CcSEcCtD
Methazolamide—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.0004	0.0285	CbGpPWpGaD
Methazolamide—Discomfort—Triamcinolone—psoriasis	0.0004	0.00133	CcSEcCtD
Methazolamide—Fatigue—Cyclosporine—psoriasis	0.000399	0.00133	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000398	0.00132	CcSEcCtD
Methazolamide—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000398	0.00132	CcSEcCtD
Methazolamide—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000396	0.0283	CbGpPWpGaD
Methazolamide—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000393	0.0013	CcSEcCtD
Methazolamide—Anorexia—Hydrocortisone—psoriasis	0.000392	0.0013	CcSEcCtD
Methazolamide—Diarrhoea—Mycophenolic acid—psoriasis	0.000392	0.0013	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.00039	0.0013	CcSEcCtD
Methazolamide—Malaise—Betamethasone—psoriasis	0.000389	0.00129	CcSEcCtD
Methazolamide—Malaise—Dexamethasone—psoriasis	0.000389	0.00129	CcSEcCtD
Methazolamide—Anaphylactic shock—Triamcinolone—psoriasis	0.000388	0.00129	CcSEcCtD
Methazolamide—Vertigo—Dexamethasone—psoriasis	0.000387	0.00129	CcSEcCtD
Methazolamide—Vertigo—Betamethasone—psoriasis	0.000387	0.00129	CcSEcCtD
Methazolamide—Haematuria—Methotrexate—psoriasis	0.000383	0.00127	CcSEcCtD
Methazolamide—Feeling abnormal—Cyclosporine—psoriasis	0.000382	0.00127	CcSEcCtD
Methazolamide—Paraesthesia—Prednisolone—psoriasis	0.000379	0.00126	CcSEcCtD
Methazolamide—Agranulocytosis—Methotrexate—psoriasis	0.000375	0.00124	CcSEcCtD
Methazolamide—Convulsion—Betamethasone—psoriasis	0.000373	0.00124	CcSEcCtD
Methazolamide—Convulsion—Dexamethasone—psoriasis	0.000373	0.00124	CcSEcCtD
Methazolamide—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000372	0.00124	CcSEcCtD
Methazolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—VEGFA—psoriasis	0.000371	0.0264	CbGpPWpGaD
Methazolamide—Paraesthesia—Hydrocortisone—psoriasis	0.00037	0.00123	CcSEcCtD
Methazolamide—Urticaria—Cyclosporine—psoriasis	0.000368	0.00122	CcSEcCtD
Methazolamide—Body temperature increased—Cyclosporine—psoriasis	0.000366	0.00122	CcSEcCtD
Methazolamide—Vomiting—Mycophenolic acid—psoriasis	0.000364	0.00121	CcSEcCtD
Methazolamide—Discomfort—Betamethasone—psoriasis	0.000363	0.0012	CcSEcCtD
Methazolamide—Discomfort—Dexamethasone—psoriasis	0.000363	0.0012	CcSEcCtD
Methazolamide—Dyspepsia—Hydrocortisone—psoriasis	0.000362	0.0012	CcSEcCtD
Methazolamide—Rash—Mycophenolic acid—psoriasis	0.000361	0.0012	CcSEcCtD
Methazolamide—Dermatitis—Mycophenolic acid—psoriasis	0.000361	0.0012	CcSEcCtD
Methazolamide—Urticaria—Mycophenolate mofetil—psoriasis	0.000359	0.00119	CcSEcCtD
Methazolamide—Headache—Mycophenolic acid—psoriasis	0.000359	0.00119	CcSEcCtD
Methazolamide—Decreased appetite—Hydrocortisone—psoriasis	0.000358	0.00119	CcSEcCtD
Methazolamide—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000357	0.00119	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000355	0.00118	CcSEcCtD
Methazolamide—Fatigue—Hydrocortisone—psoriasis	0.000355	0.00118	CcSEcCtD
Methazolamide—Anaphylactic shock—Dexamethasone—psoriasis	0.000352	0.00117	CcSEcCtD
Methazolamide—Anaphylactic shock—Betamethasone—psoriasis	0.000352	0.00117	CcSEcCtD
Methazolamide—Ill-defined disorder—Prednisone—psoriasis	0.000348	0.00116	CcSEcCtD
Methazolamide—Paraesthesia—Triamcinolone—psoriasis	0.000348	0.00116	CcSEcCtD
Methazolamide—Feeling abnormal—Prednisolone—psoriasis	0.000347	0.00115	CcSEcCtD
Methazolamide—Dyspepsia—Triamcinolone—psoriasis	0.000341	0.00113	CcSEcCtD
Methazolamide—Erythema multiforme—Methotrexate—psoriasis	0.000341	0.00113	CcSEcCtD
Methazolamide—Nausea—Mycophenolic acid—psoriasis	0.00034	0.00113	CcSEcCtD
Methazolamide—Feeling abnormal—Hydrocortisone—psoriasis	0.000339	0.00113	CcSEcCtD
Methazolamide—Malaise—Prednisone—psoriasis	0.000339	0.00112	CcSEcCtD
Methazolamide—Vertigo—Prednisone—psoriasis	0.000337	0.00112	CcSEcCtD
Methazolamide—Tinnitus—Methotrexate—psoriasis	0.000336	0.00112	CcSEcCtD
Methazolamide—Anorexia—Betamethasone—psoriasis	0.000335	0.00111	CcSEcCtD
Methazolamide—Anorexia—Dexamethasone—psoriasis	0.000335	0.00111	CcSEcCtD
Methazolamide—Urticaria—Prednisolone—psoriasis	0.000335	0.00111	CcSEcCtD
Methazolamide—Fatigue—Triamcinolone—psoriasis	0.000334	0.00111	CcSEcCtD
Methazolamide—Asthenia—Cyclosporine—psoriasis	0.000332	0.0011	CcSEcCtD
Methazolamide—Urticaria—Hydrocortisone—psoriasis	0.000327	0.00109	CcSEcCtD
Methazolamide—Body temperature increased—Hydrocortisone—psoriasis	0.000325	0.00108	CcSEcCtD
Methazolamide—Convulsion—Prednisone—psoriasis	0.000325	0.00108	CcSEcCtD
Methazolamide—Asthenia—Mycophenolate mofetil—psoriasis	0.000324	0.00108	CcSEcCtD
Methazolamide—Feeling abnormal—Triamcinolone—psoriasis	0.000319	0.00106	CcSEcCtD
Methazolamide—Diarrhoea—Cyclosporine—psoriasis	0.000317	0.00105	CcSEcCtD
Methazolamide—Paraesthesia—Betamethasone—psoriasis	0.000316	0.00105	CcSEcCtD
Methazolamide—Paraesthesia—Dexamethasone—psoriasis	0.000316	0.00105	CcSEcCtD
Methazolamide—Discomfort—Prednisone—psoriasis	0.000316	0.00105	CcSEcCtD
Methazolamide—Dyspepsia—Dexamethasone—psoriasis	0.00031	0.00103	CcSEcCtD
Methazolamide—Dyspepsia—Betamethasone—psoriasis	0.00031	0.00103	CcSEcCtD
Methazolamide—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000309	0.00103	CcSEcCtD
Methazolamide—Urticaria—Triamcinolone—psoriasis	0.000308	0.00102	CcSEcCtD
Methazolamide—Dysgeusia—Methotrexate—psoriasis	0.000307	0.00102	CcSEcCtD
Methazolamide—Body temperature increased—Triamcinolone—psoriasis	0.000306	0.00102	CcSEcCtD
Methazolamide—Anaphylactic shock—Prednisone—psoriasis	0.000306	0.00102	CcSEcCtD
Methazolamide—CA9—HIF-1-alpha transcription factor network—CP—psoriasis	0.000306	0.0218	CbGpPWpGaD
Methazolamide—Decreased appetite—Dexamethasone—psoriasis	0.000306	0.00101	CcSEcCtD
Methazolamide—Decreased appetite—Betamethasone—psoriasis	0.000306	0.00101	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000304	0.00101	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Betamethasone—psoriasis	0.000304	0.00101	CcSEcCtD
Methazolamide—Fatigue—Betamethasone—psoriasis	0.000303	0.00101	CcSEcCtD
Methazolamide—Fatigue—Dexamethasone—psoriasis	0.000303	0.00101	CcSEcCtD
Methazolamide—Asthenia—Hydrocortisone—psoriasis	0.000295	0.00098	CcSEcCtD
Methazolamide—Vomiting—Cyclosporine—psoriasis	0.000295	0.000978	CcSEcCtD
Methazolamide—Rash—Cyclosporine—psoriasis	0.000292	0.00097	CcSEcCtD
Methazolamide—Anorexia—Prednisone—psoriasis	0.000292	0.000969	CcSEcCtD
Methazolamide—Dermatitis—Cyclosporine—psoriasis	0.000292	0.000969	CcSEcCtD
Methazolamide—Ill-defined disorder—Methotrexate—psoriasis	0.000291	0.000966	CcSEcCtD
Methazolamide—Headache—Cyclosporine—psoriasis	0.00029	0.000963	CcSEcCtD
Methazolamide—Feeling abnormal—Dexamethasone—psoriasis	0.00029	0.000962	CcSEcCtD
Methazolamide—Feeling abnormal—Betamethasone—psoriasis	0.00029	0.000962	CcSEcCtD
Methazolamide—Vomiting—Mycophenolate mofetil—psoriasis	0.000287	0.000954	CcSEcCtD
Methazolamide—Rash—Mycophenolate mofetil—psoriasis	0.000285	0.000946	CcSEcCtD
Methazolamide—Dermatitis—Mycophenolate mofetil—psoriasis	0.000285	0.000945	CcSEcCtD
Methazolamide—Headache—Mycophenolate mofetil—psoriasis	0.000283	0.00094	CcSEcCtD
Methazolamide—Malaise—Methotrexate—psoriasis	0.000283	0.000939	CcSEcCtD
Methazolamide—Vertigo—Methotrexate—psoriasis	0.000282	0.000935	CcSEcCtD
Methazolamide—Diarrhoea—Hydrocortisone—psoriasis	0.000282	0.000935	CcSEcCtD
Methazolamide—Leukopenia—Methotrexate—psoriasis	0.000281	0.000932	CcSEcCtD
Methazolamide—Urticaria—Dexamethasone—psoriasis	0.000279	0.000928	CcSEcCtD
Methazolamide—Urticaria—Betamethasone—psoriasis	0.000279	0.000928	CcSEcCtD
Methazolamide—Asthenia—Triamcinolone—psoriasis	0.000278	0.000923	CcSEcCtD
Methazolamide—Body temperature increased—Dexamethasone—psoriasis	0.000278	0.000923	CcSEcCtD
Methazolamide—Body temperature increased—Betamethasone—psoriasis	0.000278	0.000923	CcSEcCtD
Methazolamide—Nausea—Cyclosporine—psoriasis	0.000275	0.000913	CcSEcCtD
Methazolamide—Paraesthesia—Prednisone—psoriasis	0.000275	0.000913	CcSEcCtD
Methazolamide—Convulsion—Methotrexate—psoriasis	0.000272	0.000902	CcSEcCtD
Methazolamide—Dyspepsia—Prednisone—psoriasis	0.00027	0.000895	CcSEcCtD
Methazolamide—Nausea—Mycophenolate mofetil—psoriasis	0.000268	0.000891	CcSEcCtD
Methazolamide—Decreased appetite—Prednisone—psoriasis	0.000266	0.000884	CcSEcCtD
Methazolamide—Rash—Prednisolone—psoriasis	0.000266	0.000882	CcSEcCtD
Methazolamide—Dermatitis—Prednisolone—psoriasis	0.000266	0.000881	CcSEcCtD
Methazolamide—Fatigue—Prednisone—psoriasis	0.000264	0.000877	CcSEcCtD
Methazolamide—Headache—Prednisolone—psoriasis	0.000264	0.000877	CcSEcCtD
Methazolamide—Discomfort—Methotrexate—psoriasis	0.000264	0.000876	CcSEcCtD
Methazolamide—Vomiting—Hydrocortisone—psoriasis	0.000262	0.000869	CcSEcCtD
Methazolamide—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000261	0.0186	CbGpPWpGaD
Methazolamide—Rash—Hydrocortisone—psoriasis	0.00026	0.000862	CcSEcCtD
Methazolamide—Dermatitis—Hydrocortisone—psoriasis	0.000259	0.000861	CcSEcCtD
Methazolamide—Confusional state—Methotrexate—psoriasis	0.000258	0.000857	CcSEcCtD
Methazolamide—Headache—Hydrocortisone—psoriasis	0.000258	0.000856	CcSEcCtD
Methazolamide—Anaphylactic shock—Methotrexate—psoriasis	0.000256	0.00085	CcSEcCtD
Methazolamide—Feeling abnormal—Prednisone—psoriasis	0.000252	0.000838	CcSEcCtD
Methazolamide—Asthenia—Betamethasone—psoriasis	0.000252	0.000838	CcSEcCtD
Methazolamide—Asthenia—Dexamethasone—psoriasis	0.000252	0.000838	CcSEcCtD
Methazolamide—Nausea—Prednisolone—psoriasis	0.00025	0.000831	CcSEcCtD
Methazolamide—Vomiting—Triamcinolone—psoriasis	0.000247	0.000818	CcSEcCtD
Methazolamide—Nausea—Hydrocortisone—psoriasis	0.000245	0.000812	CcSEcCtD
Methazolamide—Rash—Triamcinolone—psoriasis	0.000244	0.000811	CcSEcCtD
Methazolamide—Dermatitis—Triamcinolone—psoriasis	0.000244	0.000811	CcSEcCtD
Methazolamide—Anorexia—Methotrexate—psoriasis	0.000244	0.00081	CcSEcCtD
Methazolamide—Urticaria—Prednisone—psoriasis	0.000243	0.000808	CcSEcCtD
Methazolamide—Headache—Triamcinolone—psoriasis	0.000243	0.000806	CcSEcCtD
Methazolamide—Body temperature increased—Prednisone—psoriasis	0.000242	0.000804	CcSEcCtD
Methazolamide—Diarrhoea—Dexamethasone—psoriasis	0.000241	0.000799	CcSEcCtD
Methazolamide—Diarrhoea—Betamethasone—psoriasis	0.000241	0.000799	CcSEcCtD
Methazolamide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000234	0.0167	CbGpPWpGaD
Methazolamide—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000231	0.0165	CbGpPWpGaD
Methazolamide—Nausea—Triamcinolone—psoriasis	0.00023	0.000764	CcSEcCtD
Methazolamide—Paraesthesia—Methotrexate—psoriasis	0.00023	0.000763	CcSEcCtD
Methazolamide—Somnolence—Methotrexate—psoriasis	0.000228	0.000755	CcSEcCtD
Methazolamide—Dyspepsia—Methotrexate—psoriasis	0.000225	0.000748	CcSEcCtD
Methazolamide—Vomiting—Betamethasone—psoriasis	0.000224	0.000742	CcSEcCtD
Methazolamide—Vomiting—Dexamethasone—psoriasis	0.000224	0.000742	CcSEcCtD
Methazolamide—Decreased appetite—Methotrexate—psoriasis	0.000223	0.000739	CcSEcCtD
Methazolamide—Rash—Dexamethasone—psoriasis	0.000222	0.000736	CcSEcCtD
Methazolamide—Rash—Betamethasone—psoriasis	0.000222	0.000736	CcSEcCtD
Methazolamide—Dermatitis—Betamethasone—psoriasis	0.000222	0.000735	CcSEcCtD
Methazolamide—Dermatitis—Dexamethasone—psoriasis	0.000222	0.000735	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Methotrexate—psoriasis	0.000221	0.000734	CcSEcCtD
Methazolamide—Fatigue—Methotrexate—psoriasis	0.000221	0.000733	CcSEcCtD
Methazolamide—Headache—Dexamethasone—psoriasis	0.00022	0.000731	CcSEcCtD
Methazolamide—Headache—Betamethasone—psoriasis	0.00022	0.000731	CcSEcCtD
Methazolamide—Asthenia—Prednisone—psoriasis	0.00022	0.00073	CcSEcCtD
Methazolamide—Feeling abnormal—Methotrexate—psoriasis	0.000211	0.0007	CcSEcCtD
Methazolamide—Diarrhoea—Prednisone—psoriasis	0.00021	0.000696	CcSEcCtD
Methazolamide—Nausea—Dexamethasone—psoriasis	0.000209	0.000694	CcSEcCtD
Methazolamide—Nausea—Betamethasone—psoriasis	0.000209	0.000694	CcSEcCtD
Methazolamide—Urticaria—Methotrexate—psoriasis	0.000203	0.000675	CcSEcCtD
Methazolamide—Body temperature increased—Methotrexate—psoriasis	0.000202	0.000672	CcSEcCtD
Methazolamide—Vomiting—Prednisone—psoriasis	0.000195	0.000646	CcSEcCtD
Methazolamide—Rash—Prednisone—psoriasis	0.000193	0.000641	CcSEcCtD
Methazolamide—Dermatitis—Prednisone—psoriasis	0.000193	0.000641	CcSEcCtD
Methazolamide—Headache—Prednisone—psoriasis	0.000192	0.000637	CcSEcCtD
Methazolamide—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00019	0.0135	CbGpPWpGaD
Methazolamide—Asthenia—Methotrexate—psoriasis	0.000184	0.00061	CcSEcCtD
Methazolamide—Nausea—Prednisone—psoriasis	0.000182	0.000604	CcSEcCtD
Methazolamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000181	0.0129	CbGpPWpGaD
Methazolamide—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000178	0.0127	CbGpPWpGaD
Methazolamide—Diarrhoea—Methotrexate—psoriasis	0.000175	0.000581	CcSEcCtD
Methazolamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000166	0.0118	CbGpPWpGaD
Methazolamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000165	0.0117	CbGpPWpGaD
Methazolamide—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000164	0.0117	CbGpPWpGaD
Methazolamide—CA9—Cellular response to hypoxia—VEGFA—psoriasis	0.000164	0.0117	CbGpPWpGaD
Methazolamide—Vomiting—Methotrexate—psoriasis	0.000163	0.00054	CcSEcCtD
Methazolamide—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000162	0.0116	CbGpPWpGaD
Methazolamide—Rash—Methotrexate—psoriasis	0.000161	0.000536	CcSEcCtD
Methazolamide—Dermatitis—Methotrexate—psoriasis	0.000161	0.000535	CcSEcCtD
Methazolamide—Headache—Methotrexate—psoriasis	0.00016	0.000532	CcSEcCtD
Methazolamide—Nausea—Methotrexate—psoriasis	0.000152	0.000505	CcSEcCtD
Methazolamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000146	0.0104	CbGpPWpGaD
Methazolamide—CA9—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000139	0.00994	CbGpPWpGaD
Methazolamide—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000135	0.00961	CbGpPWpGaD
Methazolamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000135	0.00959	CbGpPWpGaD
Methazolamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000133	0.00951	CbGpPWpGaD
Methazolamide—CA9—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.00013	0.00926	CbGpPWpGaD
Methazolamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000109	0.00774	CbGpPWpGaD
Methazolamide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000107	0.00766	CbGpPWpGaD
Methazolamide—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000107	0.00764	CbGpPWpGaD
Methazolamide—CA14—Metabolism—NDUFA5—psoriasis	0.000103	0.00733	CbGpPWpGaD
Methazolamide—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000101	0.00718	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—NDUFA5—psoriasis	0.0001	0.00714	CbGpPWpGaD
Methazolamide—CA6—Metabolism—NDUFA5—psoriasis	0.0001	0.00714	CbGpPWpGaD
Methazolamide—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	9.94e-05	0.00708	CbGpPWpGaD
Methazolamide—CA7—Metabolism—NDUFA5—psoriasis	9.36e-05	0.00667	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—NDUFA5—psoriasis	9.36e-05	0.00667	CbGpPWpGaD
Methazolamide—CA1—C-MYB transcription factor network—CD4—psoriasis	9.03e-05	0.00643	CbGpPWpGaD
Methazolamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	8.8e-05	0.00627	CbGpPWpGaD
Methazolamide—CA14—Metabolism—CYP2S1—psoriasis	8.74e-05	0.00623	CbGpPWpGaD
Methazolamide—CYP2E1—Tryptophan metabolism—CAT—psoriasis	8.69e-05	0.0062	CbGpPWpGaD
Methazolamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	8.68e-05	0.00619	CbGpPWpGaD
Methazolamide—CA12—Metabolism—NDUFA5—psoriasis	8.67e-05	0.00618	CbGpPWpGaD
Methazolamide—CA9—HIF-1-alpha transcription factor network—JUN—psoriasis	8.62e-05	0.00614	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—CYP2S1—psoriasis	8.52e-05	0.00607	CbGpPWpGaD
Methazolamide—CA6—Metabolism—CYP2S1—psoriasis	8.52e-05	0.00607	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—CYP2S1—psoriasis	7.96e-05	0.00567	CbGpPWpGaD
Methazolamide—CA7—Metabolism—CYP2S1—psoriasis	7.96e-05	0.00567	CbGpPWpGaD
Methazolamide—CYP2C19—Biological oxidations—CYP2S1—psoriasis	7.77e-05	0.00554	CbGpPWpGaD
Methazolamide—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	7.67e-05	0.00546	CbGpPWpGaD
Methazolamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.56e-05	0.00539	CbGpPWpGaD
Methazolamide—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	7.54e-05	0.00537	CbGpPWpGaD
Methazolamide—CA9—HIF-1-alpha transcription factor network—VEGFA—psoriasis	7.53e-05	0.00536	CbGpPWpGaD
Methazolamide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.49e-05	0.00534	CbGpPWpGaD
Methazolamide—CA12—Metabolism—CYP2S1—psoriasis	7.37e-05	0.00525	CbGpPWpGaD
Methazolamide—CYP2D6—Biological oxidations—CYP2S1—psoriasis	7.15e-05	0.0051	CbGpPWpGaD
Methazolamide—CYP2C9—Biological oxidations—CYP2S1—psoriasis	7.09e-05	0.00505	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	7.05e-05	0.00503	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	6.99e-05	0.00498	CbGpPWpGaD
Methazolamide—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	6.93e-05	0.00494	CbGpPWpGaD
Methazolamide—CA4—Metabolism—NDUFA5—psoriasis	6.91e-05	0.00493	CbGpPWpGaD
Methazolamide—CA2—Metabolism—NDUFA5—psoriasis	6.63e-05	0.00472	CbGpPWpGaD
Methazolamide—CA1—Metabolism—NDUFA5—psoriasis	6.35e-05	0.00453	CbGpPWpGaD
Methazolamide—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	6.13e-05	0.00437	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—CAT—psoriasis	5.92e-05	0.00422	CbGpPWpGaD
Methazolamide—CA4—Metabolism—CYP2S1—psoriasis	5.88e-05	0.00419	CbGpPWpGaD
Methazolamide—CA2—Metabolism—CYP2S1—psoriasis	5.63e-05	0.00402	CbGpPWpGaD
Methazolamide—CA9—Metabolism—NDUFA5—psoriasis	5.59e-05	0.00398	CbGpPWpGaD
Methazolamide—CA1—Metabolism—CYP2S1—psoriasis	5.4e-05	0.00385	CbGpPWpGaD
Methazolamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.27e-05	0.00376	CbGpPWpGaD
Methazolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.99e-05	0.00355	CbGpPWpGaD
Methazolamide—CA9—Metabolism—CYP2S1—psoriasis	4.75e-05	0.00338	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—CYP2S1—psoriasis	4.68e-05	0.00333	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	4.61e-05	0.00329	CbGpPWpGaD
Methazolamide—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	4.48e-05	0.00319	CbGpPWpGaD
Methazolamide—CA14—Metabolism—CARM1—psoriasis	4.27e-05	0.00304	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—CARM1—psoriasis	4.16e-05	0.00297	CbGpPWpGaD
Methazolamide—CA6—Metabolism—CARM1—psoriasis	4.16e-05	0.00297	CbGpPWpGaD
Methazolamide—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	4.12e-05	0.00294	CbGpPWpGaD
Methazolamide—CYP3A4—Tryptophan metabolism—CAT—psoriasis	4.03e-05	0.00287	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—CARM1—psoriasis	3.89e-05	0.00277	CbGpPWpGaD
Methazolamide—CA7—Metabolism—CARM1—psoriasis	3.89e-05	0.00277	CbGpPWpGaD
Methazolamide—CA12—Metabolism—CARM1—psoriasis	3.6e-05	0.00257	CbGpPWpGaD
Methazolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.48e-05	0.00248	CbGpPWpGaD
Methazolamide—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	3.11e-05	0.00222	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—CXCL8—psoriasis	3.06e-05	0.00218	CbGpPWpGaD
Methazolamide—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	2.97e-05	0.00212	CbGpPWpGaD
Methazolamide—CA4—Metabolism—CARM1—psoriasis	2.87e-05	0.00205	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—JUN—psoriasis	2.84e-05	0.00203	CbGpPWpGaD
Methazolamide—CA2—Metabolism—CARM1—psoriasis	2.75e-05	0.00196	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—NFKB1—psoriasis	2.74e-05	0.00195	CbGpPWpGaD
Methazolamide—CA1—Metabolism—CARM1—psoriasis	2.64e-05	0.00188	CbGpPWpGaD
Methazolamide—CA14—Metabolism—CAT—psoriasis	2.63e-05	0.00187	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—CAT—psoriasis	2.56e-05	0.00182	CbGpPWpGaD
Methazolamide—CA6—Metabolism—CAT—psoriasis	2.56e-05	0.00182	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—VEGFA—psoriasis	2.48e-05	0.00177	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—STAT3—psoriasis	2.46e-05	0.00175	CbGpPWpGaD
Methazolamide—CA7—Metabolism—CAT—psoriasis	2.39e-05	0.0017	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—CAT—psoriasis	2.39e-05	0.0017	CbGpPWpGaD
Methazolamide—CA9—Metabolism—CARM1—psoriasis	2.32e-05	0.00165	CbGpPWpGaD
Methazolamide—CA12—Metabolism—CAT—psoriasis	2.21e-05	0.00158	CbGpPWpGaD
Methazolamide—CA14—Metabolism—APOE—psoriasis	2.04e-05	0.00145	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NDUFA5—psoriasis	2.03e-05	0.00144	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—APOE—psoriasis	1.99e-05	0.00142	CbGpPWpGaD
Methazolamide—CA6—Metabolism—APOE—psoriasis	1.99e-05	0.00142	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—TP53—psoriasis	1.88e-05	0.00134	CbGpPWpGaD
Methazolamide—CA7—Metabolism—APOE—psoriasis	1.86e-05	0.00132	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—APOE—psoriasis	1.86e-05	0.00132	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PPARG—psoriasis	1.78e-05	0.00127	CbGpPWpGaD
Methazolamide—CA4—Metabolism—CAT—psoriasis	1.77e-05	0.00126	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PPARG—psoriasis	1.73e-05	0.00123	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PPARG—psoriasis	1.73e-05	0.00123	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CYP2S1—psoriasis	1.72e-05	0.00123	CbGpPWpGaD
Methazolamide—CA12—Metabolism—APOE—psoriasis	1.72e-05	0.00123	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—IL6—psoriasis	1.72e-05	0.00122	CbGpPWpGaD
Methazolamide—CA2—Metabolism—CAT—psoriasis	1.69e-05	0.00121	CbGpPWpGaD
Methazolamide—CA1—Metabolism—CAT—psoriasis	1.62e-05	0.00116	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PPARG—psoriasis	1.62e-05	0.00115	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PPARG—psoriasis	1.62e-05	0.00115	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NDUFA5—psoriasis	1.56e-05	0.00111	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PPARG—psoriasis	1.5e-05	0.00107	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.46e-05	0.00104	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NDUFA5—psoriasis	1.44e-05	0.00102	CbGpPWpGaD
Methazolamide—CA9—Metabolism—CAT—psoriasis	1.43e-05	0.00102	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NDUFA5—psoriasis	1.43e-05	0.00102	CbGpPWpGaD
Methazolamide—CA4—Metabolism—APOE—psoriasis	1.37e-05	0.000978	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CYP2S1—psoriasis	1.33e-05	0.000948	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.33e-05	0.000947	CbGpPWpGaD
Methazolamide—CA2—Metabolism—APOE—psoriasis	1.32e-05	0.000937	CbGpPWpGaD
Methazolamide—CA1—Metabolism—APOE—psoriasis	1.26e-05	0.000899	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CYP2S1—psoriasis	1.22e-05	0.000872	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CYP2S1—psoriasis	1.21e-05	0.000864	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PPARG—psoriasis	1.19e-05	0.000852	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PPARG—psoriasis	1.15e-05	0.000816	CbGpPWpGaD
Methazolamide—CA9—Metabolism—APOE—psoriasis	1.11e-05	0.00079	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PPARG—psoriasis	1.1e-05	0.000783	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PPARG—psoriasis	9.65e-06	0.000688	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NDUFA5—psoriasis	9.4e-06	0.00067	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CARM1—psoriasis	8.42e-06	0.0006	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CYP2S1—psoriasis	8e-06	0.00057	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.97e-06	0.000497	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CARM1—psoriasis	6.49e-06	0.000463	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.35e-06	0.000453	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.07e-06	0.000433	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CARM1—psoriasis	5.97e-06	0.000426	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CARM1—psoriasis	5.92e-06	0.000422	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.53e-06	0.000394	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CAT—psoriasis	5.18e-06	0.000369	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—APOE—psoriasis	4.02e-06	0.000287	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CAT—psoriasis	3.99e-06	0.000285	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CARM1—psoriasis	3.9e-06	0.000278	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CAT—psoriasis	3.67e-06	0.000262	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CAT—psoriasis	3.64e-06	0.00026	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PPARG—psoriasis	3.5e-06	0.00025	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—APOE—psoriasis	3.1e-06	0.000221	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—APOE—psoriasis	2.85e-06	0.000203	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—APOE—psoriasis	2.83e-06	0.000202	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PPARG—psoriasis	2.7e-06	0.000193	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PPARG—psoriasis	2.49e-06	0.000177	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PPARG—psoriasis	2.46e-06	0.000176	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CAT—psoriasis	2.4e-06	0.000171	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—APOE—psoriasis	1.87e-06	0.000133	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PPARG—psoriasis	1.63e-06	0.000116	CbGpPWpGaD
